

Clive A Holmes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8138411/publications.pdf>

Version: 2024-02-01

45
papers

16,128
citations

147801

31
h-index

214800

47
g-index

49
all docs

49
docs citations

49
times ranked

22279
citing authors

#	ARTICLE	IF	CITATIONS
1	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
2	A case-control study of the locus coeruleus degeneration in Alzheimer's disease. <i>European Neuropsychopharmacology</i> , 2021, 43, 153-159.	0.7	20
3	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
4	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 5-22.	2.6	52
5	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. <i>Translational Psychiatry</i> , 2020, 10, 267.	4.8	30
6	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1219-1226.	1.9	17
7	Psychological stress, cognitive decline and the development of dementia in amnesic mild cognitive impairment. <i>Scientific Reports</i> , 2020, 10, 3618.	3.3	21
8	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0218111.	2.5	23
9	Microglial motility in Alzheimer's disease and after A β 242 immunotherapy: a human post-mortem study. <i>Acta Neuropathologica Communications</i> , 2019, 7, 174.	5.2	35
10	Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. <i>Translational Psychiatry</i> , 2019, 9, 154.	4.8	69
11	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
12	Downregulated apoptosis and autophagy after anti-A β 2 immunotherapy in Alzheimer's disease. <i>Brain Pathology</i> , 2018, 28, 603-610.	4.1	24
13	Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 88.	5.2	52
14	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 212-218.	4.1	132
15	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the Tj ETQq1 1 0.784314 rgBT /Overload	2.7	48
16	EMERGING CONCEPTS IN BASIC SCIENCE: PANEL SESSION. <i>Alzheimer's and Dementia</i> , 2017, 13, P1224.	0.8	0
17	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. <i>PLoS ONE</i> , 2017, 12, e0179521.	2.5	48
18	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 85.	6.2	52

#	ARTICLE	IF	CITATIONS
19	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017, 21, 1-192.	2.8	37
20	Targeting innate immunity for neurodegenerative disorders of the central nervous system. <i>Journal of Neurochemistry</i> , 2016, 138, 653-693.	3.9	106
21	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. <i>Trials</i> , 2016, 17, 324.	1.6	6
22	Periodontitis and Cognitive Decline in Alzheimer's Disease. <i>PLoS ONE</i> , 2016, 11, e0151081.	2.5	289
23	Etanercept in Alzheimer disease. <i>Neurology</i> , 2015, 84, 2161-2168.	1.1	203
24	Effect of amyloid β immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase-3 β . <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 445-457.	3.2	17
25	Neuroinflammation in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2015, 14, 388-405.	10.2	4,129
26	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , The, 2015, 14, 1171-1181.	10.2	124
27	Common polygenic variation enhances risk prediction for Alzheimer's disease. <i>Brain</i> , 2015, 138, 3673-3684.	7.6	359
28	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.8	173
29	Microglial priming in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2014, 10, 217-224.	10.1	827
30	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	2.5	155
31	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	21.4	3,741
32	Intravenous immunoglobulin for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2013, 12, 218-219.	10.2	6
33	Systemic inflammation and Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2011, 39, 898-901.	3.4	67
34	Determining the minimum clinically important differences for outcomes in the DOMINO trial. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 812-817.	2.7	126
35	Role of Infection in the Pathogenesis of Alzheimer's Disease. <i>CNS Drugs</i> , 2009, 23, 993-1002.	5.9	66
36	Long-term effects of A β 242 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. <i>Lancet</i> , The, 2008, 372, 216-223.	13.7	1,333

#	ARTICLE	IF	CITATIONS
37	Keep music live: music and the alleviation of apathy in dementia subjects. <i>International Psychogeriatrics</i> , 2006, 18, 623-630.	1.0	133
38	Reply to "Specificity of mechanisms for plaque removal after A β 2 immunotherapy for Alzheimer disease". <i>Nature Medicine</i> , 2004, 10, 118-119.	30.7	12
39	Depression in Alzheimer's disease: The effect of serotonin receptor gene variation. <i>American Journal of Medical Genetics Part A</i> , 2003, 119B, 40-43.	2.4	58
40	Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. <i>Age and Ageing</i> , 2003, 32, 200-204.	1.6	71
41	Genotype and phenotype in Alzheimer's disease. <i>British Journal of Psychiatry</i> , 2002, 180, 131-134.	2.8	91
42	The clinical phenotype of familial and sporadic late onset Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 146-149.	2.7	14
43	Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 305-308.	2.7	159
44	Contribution of Genetics to the Understanding of Behavioral and Psychological Symptoms of Dementia. <i>International Psychogeriatrics</i> , 2000, 12, 83-88.	1.0	5
45	Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. <i>British Journal of Psychiatry</i> , 1999, 174, 45-50.	2.8	329